A new experimental pill, enlicitide, has shown remarkable results in lowering cholesterol levels in individuals at high risk of heart attacks despite taking statins. Researchers reported in the New England Journal of Medicine that enlicitide users experienced a 60% reduction in LDL cholesterol over six months. This is a significant improvement compared to other pills that can be added to statins, which only offer a fraction of the same effect. The study, funded by Merck, provides compelling evidence that enlicitide could be a game-changer for those seeking an easier-to-use option for managing high cholesterol. However, it's important to note that the pill must be taken on an empty stomach, and further studies are needed to determine its long-term impact on heart attacks, strokes, and mortality.
